Prevention of Heart Failure

Профилактика сердечной недостаточности
Daniel A Levy, Harlan M. Krumholz, George A. Mensah, Gregg C. Fonarow, Jagat Narula, Yuling Hong, Emelia J. Benjamin, Douglas D. Schocken, Eileen Stuart‐Shor, James B. Young
2008-04-08

asymptomatic left ventricular systolic dysfunctionbiomarkerscoronary heart diseaseheart failure preventionhypertension
The increase in heart failure (HF) rates throughout the developed and developing regions of the world poses enormous challenges for caregivers, researchers, and policymakers. Therefore, prevention of this global scourge deserves high priority. Identifying and preventing the well-recognized illnesses that lead to HF, including hypertension and coronary heart disease, should be paramount among the approaches to prevent HF. Aggressive implementation of evidence-based management of risk factors for coronary heart disease should be at the core of HF prevention strategies. Questions currently in need of attention include how to identify and treat patients with asymptomatic left ventricular systolic dysfunction (Stage B HF) and how to prevent its development. The relationship of chronic kidney disease to HF and control of chronic kidney disease in prevention of HF need further investigation. Currently, we have limited understanding of the pathophysiological basis of HF in patients with preserved left ventricular systolic function and management techniques to prevent it. New developments in the field of biomarker identification have opened possibilities for the early detection of individuals at risk for developing HF (Stage A HF). Patient groups meriting special interest include the elderly, women, and ethnic/racial minorities. Future research ought to focus on obtaining a much better knowledge of genetics and HF, especially both genetic risk factors for development of HF and genetic markers as tools to guide prevention. Lastly, a national awareness campaign should be created and implemented to increase public awareness of HF and the importance of its prevention. Heightened public awareness will provide a platform for advocacy to create national research programs and healthcare policies dedicated to the prevention of HF.
1
Biomarker discovery may enable earlier identification of individuals at risk for heart failure, while genetic research could improve risk prediction and prevention guidance.
2
Effective identification and treatment strategies for asymptomatic left ventricular systolic dysfunction (Stage B heart failure) remain important unmet needs.
3
National public-awareness campaigns are needed to promote heart-failure prevention and support research programs and healthcare policies.
4
Preventing hypertension, coronary heart disease, and other established precursors through aggressive evidence-based risk-factor management is central to heart-failure prevention.
5
Prevention strategies are limited by incomplete understanding of heart failure with preserved left ventricular systolic function and its pathophysiology.
6
The relationship between chronic kidney disease and heart failure, including whether kidney-disease control prevents heart failure, requires further investigation.

heart failure and its at-risk or precursor populations

prevention of heart failure through risk-factor management, early identification of precursor conditions, and elucidation of genetic and pathophysiological mechanisms

Publication Details
Publication Date
2008-04-08
Journal
Publisher
ISSN
Cited by
553
Access Type
Author Information
Authors
Daniel A Levy
Harlan M. Krumholz
George A. Mensah
Gregg C. Fonarow
Jagat Narula
Yuling Hong
Emelia J. Benjamin
Douglas D. Schocken
Eileen Stuart‐Shor
James B. Young
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%